联合药物治疗盐敏感性高血压的疗效分析

摘要

目的：探讨联合药物治疗对盐敏感性高血压患者的疗效及靶器官功能的影响。方法回顾性分析125例符合标准的盐敏感性高血压患者，并将其分为2组，分别予安博诺以及非洛地平联合厄贝沙坦治疗8周，观察治疗期间血压的变化及左室重量指数（LVMI）、空腹血糖（FPG）、总胆固醇（TC）、总甘油三酯（TG）、血β2微球蛋白（β2－MG）的变化水平。结果安博诺组与非洛地平联合厄贝沙坦联合治疗组的患者相比，4周和8周时的降压幅度较少，但两组患者的降压有效性均高达81．0％及83．9％，差异无显著的统计学意义。然而安博诺组的患者治疗后LVMI明显下调（28．9±7．3），降压幅度明显优于非洛地平联合厄贝沙坦联合治疗组；此外两组患者其余各项指标治疗前后均变化不大，两组间差异亦未见显著的统计学差异。结论安博诺对盐敏感性高血压患者的疗效不逊于非洛地平联合厄贝沙坦治疗，而且对心脏靶器官的功能损害保护作用更显著。%Objective To discuss the clinical effect and influence combination of drugs on the functions of target organs in the patients with salt-sensitive hypertension.Methods 125 patients with salt-sensitive hypertension, their clinical data retrospec-tively analyzed, divided into two groups, treated with coaprovel and felodipine combined with irbesartan respectively for 8 weeks.The levels of left ventricular mass index (LVMI), fasting blood glucose (FBG), triglyceride (TC), total cholesterol (TC) and blood 2-microglobulin (2-MG) during the treatment were then observed.Results The amplitude of blood pressure was significantly lower in the coaprovel group after 4 weeks and 8 weeks of treatment in the patients with salt -sensitive hypertension.However, there was no statistical difference of effectiveness between the coaprovel group ( 81.0%) and the felodipine combined with irbesartan group (83.9%).The decrease range of LVMI showed significantly better results in the coaprovel group (28.9 ±7.3).Moreover, there was no statistical difference in other indexes between two groups or before and after treatment .Conclusion Coaprovel has a similar cura-tive effect with felodipine combined with irbesartan in the treatment of patients with salt -sensitive hypertension.It has more signifi-cant protective effect for heart damage .